The objective of this paper is to assess the value of opportunistic screening in diagnosis of invasive squamous carcinoma found in >70 years old women in Trentino (Italy). 
INTRODUCTION
Since 1996, Italian national guidelines have recommended to regions, the implementation of organised screening programmes for cervical cancer. These recommendations, largely based on European guidelines, include personal invitations to women aged 25 to 64 years for a Pap smear every three years, a monitoring system, and quality assurance for each phase of the programme. Surveys designed to assess the level of implementation of organised programmes in Italy and to collect process indicators have been conducted by Italian Group for Cervical Screening since 1997 (Ronco et al., 2007) . Their results have been published by the Osservatorio Nazionale Screening (ONS) (National (OpS) , that is, left to the woman's initiative. OpS may be considered as all pap-test performed outside an OrS program. For example, some women have pap-test at their doctor's office during their physical examination, independent of personal letter invitation of OrS. An estimated 2,927 new cases of cervical cancer occurred in Italy in 2005 (crude incidence 9.7/100,000; world age-standardized incidence 6.0/100,000). 1014 (34.64%) has been diagnosed in >65 years old women (AIRTum: I Tumori in Italia -Rapporto, 2006; ISTAT, 2005) . Early diagnosis is necessary to decrease the direct management costs of disease. In the present study, we have examined the screening histories, treatment, human papillomavirus (HPV) detection of cervical intraepithelial neoplasia(CIN)3-invasive squamous cell carcinoma in >65 years-old women, diagnosed in the period 2007 to 2010 with opportunistic pap-tests in the Cytopathology Section of Institute of Anatomic Pathology of Rovereto Hospital.
MATERIALS AND METHODS
The pap-smear was performed by gynaecologist to the woman's initiative. An experienced cytopathologist (TP) whose diagnostic experience exceeds 20 years have examined all abnormal smears and 10% of the normal smears were previously observed by a senior cytotechnologist. Colposcopic and cervical biopsies were taken by an experienced colposcopist (in practice for more than 10 years) and review by a senior colposcopist as part of the routine. Consensus polymerase chain reaction (PCR) and direct sequencing of PCR products (DNA HPV typing) were used to determinate the type or types of human papillomavirus (HPV) in histological specimens.
RESULTS
The distribution of women for decades is reported in Table 1 . Between the women >64 years-old with CIN3-squamous carcinoma, the cytological diagnosis all were > 70 years-old and were not invited to OrS because of age, > 64 years. We have reported in Table 2 , the age, histological diagnosis, treatment and HPV detection of 8 patients over 70 years, with CIN 3 squamous cell carcinoma cytological diagnosis.
DISCUSSION
There are approximately 493,000 new cases of invasive cervical cancer worldwide and 274,000 women die of the disease annually (Waterhouse et al., 1982) . The highest rates are reported in Latin America, where cervical cancer accounts for half of all female cancers. The annual incidence of invasive cervical cancer in women between 30 and 50 years of age in high-risk areas is 1/1,000. In developing countries throughout the world, cervical cancer is a major public health problem and is one of the leading causes of death (Carmichael et al., 1986) . From an epidemiological point of view, an HPV infection meets the criteria as a causal agent for cervical cancer (Schiffman et al., 1993; Bosch et al., 2002) . Having sexual contact is the main source of HPV infection. HPVs are a group of host specific DNA virus with remarkable epithelial cell specificity. More than 120 different HPV genotypes have been identified and almost 45 subtypes, isolated from the low genital tract, have been grouped into high-and low-risk HPV types, considering their risk potential to induce an invasive cervical cancer. In a recent study, Muñoz et al. (2003) classified HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73 and 82 as high risk viruses, detectable in high grade squamous intraepithelial lesions or in invasive cancer; HPV 26, 53 and 66 as potential high risk with a not well known oncogenic potential; while types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89 can be considered as viruses with low oncogenic risk and they can be isolated from low grade epithelial lesions. Functionally, high risk HPV-types infection contributes to carcinogenesis and tumour progression predominantly through the action of two viral oncogenes, E6 and E7. The E6 protein exerts rapid degradation of p53, in corporation with E6-associated protein (E6-AP), via ubiquitin-mediated proteolysis pathway . The E7 protein mediates the release of the E2F transcription factor from pRb-E2F complex (Nevins, 1992) . Mutational analysis of HPV 16 E6 protein revealed that a certain level of the activity to degrade p53 is required for E6 to manifest its transforming function (Nakagawa et al., 1992) . The p53 mutations are the most frequent genetic abnormalities found in a wide variety of human malignant tumours (Harris, 1993) . Once DNA damage occurs, p53 protein is induced and arrests cells in the G1 phase to enhance DNA repair (Kuerbitz et al., 1992) , or triggers apoptosis following DNA damage (Lowe et al., 1993) . These functions of p53 protein are important to maintain the genomic integrity. Mutant p53 proteins are devoid of these functions, because they lose the ability of DNA contact or destabilize the structure of the core domain (Cho et al., 1994) . In this way, once p53 is mutated, DNA damage is fixed and subsequent genetic rearrangement progress may be putative mechanisms to initiate cancer. Thus far, exceptionally low prevalence (0 to 6%) of the p53 mutations had been documented in cervical carcinomas (Fujita et al., 1992; Choo and Chong, 1993; Helland et al., 1993; Paquette et al., 1993; Miwa et al., 1995) . The p53 protein in cervical carcinoma is thought to be inactivated presumably due to complex formation with HPV E6 oncoprotein. The most common member of the high-risk group is HPV 16, which accounts for more than 60% of all cervical cancers. The high-risk types account for more than 95% of all cases of cervical cancer. One of the main differences between high-and low-risk types is the possibility of integration in the genome. Approximately 1% of the high-risk HPV types and only 0.1% of the lowrisk HPV types will lead to the development of cervical cancer (Ferlay et al., 2001 ). In our case, HPV 16 and HPV 58 were detected in two cases of CIN3 and HPV 58 and in one case of squamous cell carcinoma. In one case of CIN3 and in 4 cases of squamous cell carcinoma, the HPV type has been not detected. Two hypotheses may be made. There is a subset of squamous cell carcinomas that is unrelated to HPV. The other hypothesis takes into account that HPV 16 is only integrated in 72% of all invasive cervical cancers (Walboomers et al., 1999) . The finding of the absence of HPV 16 DNA integration in some carcinomas implies that integration is not always required for malignant progression, but does not exclude the importance of HPV integration in the initiation of cervical cancer. Hypothetically, after the development of a carcinoma, the abnormal clone could lose the viral DNA. HPV 18, on the other hand, shows 100% integration. In light of recent studies demonstrating that mutation of p53 gene was found in over 20% of the patients with vulvar carcinoma (Lee et al., 1994; Milde-Langosch et al., 1995) , a disease of elderly women and a known HPV-related malignancy, Nakagawa et al. (1999) The prevalence of HPV DNA was higher in the younger group than in the older group (84.0 vs. 50.0%) as was the detection rate of HPV 16 (44.0 vs. 6.3%). In contrast, HPV 18, 33, 52, 58 were frequently detected in older patients. The positive rate of p53 overexpression in the older group was similar to that in the younger group (46.7 vs. 48.8%). There was no significant difference in the incidence of lymph node metastasis, histology, and the distribution of clinical stage between the two groups.
EGFR and Cox-2 overexpression have been reported in many neoplasms (Tsujii et al., 1995; Tsujii et al., 1997) . To find information on invasive squamous cervical carcinoma in the elderly, Giordano et al. (Giordano et al., 2011) have analyzed 110 invasive squamous cervical carcinomas obtained from 2 groups of patients for HPV status In this study, 64 women 60 years or younger were designated as the younger group and 46 who were 61 years or older were designated as the older group. The HPV status and the expression of Cox-2 and EGFR in the younger and older women were compared and correlated with the grading, staging neoplasm, lymph nodal status and overall survival.
The number of neoplasms with higher staging was significantly greater than those in the younger women. The mortality was higher in the older group than in the younger patients. In the elderly, the presence of HPV DNA in 65% of cases, and in the absence of sexual activity, could be due to reactivation of latent HPV infection.
In accordance with data provided by the literature, this finding demonstrated that HPV DNA can be detected in elderly women and can be associated with cervical carcinoma (Baay et al., 2001; Garcia-Pineres et al., 2006; Subbaramaiah and Dannenberg, 2007) . Thus, it is possible that, in elderly women, HPV presence, in the absence of sexual activity, could be due to reactivation of latent HPV infection because of impairment of host immunologic response (Mubiayi et al., 2002) .
Inadequate immunologic control of HPV infection resulting in viral persistence is likely an important determinant of risk of progression to cervical neoplastic disease. Immunologic competence has been reported to decrease with aging (81 to 93). Garcia Piňeres et al. (2006) examined the association between lymphoproliferative responses to antigens/mitogens and persistent HPV infection in women older than 45 years. Women included in this study were participants in a 10,000-woman population-based cohort study of cervical neoplasia in Costa Rica. Women older than 45 years and HPV DNA positive at a screening visit were selected as cases (n = 283). Garcia Piňeres et al. selected a comparably sized control group of HPV DNA-negative women, matched women, matched to cases on age and time since enrollment (n = 261). At an additional clinical visit, women were cytologically and virologically rescreened and cervical and blood specimens were collected. Proliferative responses to phytohemagglutinin (PHA), influenza virus (Flu), and HPV16 virus-like particle (VLP) were lower among women with persistent HPV infection than for the control. The decreases were most profound in women with long-term persistence and were only observed for the oldest age group (≥65 years). The results of this study indicate that impairment in host immunologic responses is associated with persistent HPV infection.
Since 1993, at least 7 studies have described the screening histories of women with invasive cervical cancer (Ciatto et al, 1993; Kenter et al., 1996; Stuart et al., 1997) . In 2007, the almost 30% of the Italian population not included in organised programmes is partly the result of an implementation process still in progress in some regions in Southern Italy, but mainly of a very limited or completely absent implementation in a few regions in Northern Italy. In 2007, 121 active programmes had a target population of 11,872,810 women, corresponding to 71.8% of Italian women aged 25 to 64 years compared to 69% in 2006. During 2007, 39.8% of invites women were screened compared to 38.5% in the previous year. The last report of National Centre for Screening Monitoring as been published in 2008 and various process indicators of all regions have been described with exclusion of Liguria. Only 39.7% of invited women were screened, compared to 39.8% in the previous year. The data of Trentino Region has been reported in Table 3 . The data of other Italian regions has been described in Table 4 Zucchetto et al. (2010) shows that the lack of screening among older women and of compliance with organized programs among women in the target population are the main limitation in cervical cancer secondary prevention. The results of Zucchetto et al. are in agreement with research conducted in northern Europe. Bos et al. (2006) analysed the screening history of 3.175 women with invasive cervical cancer diagnosed in the years 1994 to 1997 in the Netherland. 57% of 3175 women with invasive cervical cancer had no previous smears. Given to the high proportion of women with invasive cervical cancer older than 64 years at diagnosis, the possibility of inviting them to have at least one Pap smear in life after 64 years should be taken in consideration. In according to American Cancer Society Guidelines for the early detection of cancer and the guidelines of other national regional screening programme, women 70 years of age or older who have had 3 or more normal Paptest in a know and no abnormal Pap-test results in the last 10 years may choose to stop having Paptest. According to National Cervical Screening Program the current policy of screening women of New Zealand is to continue organized regular screening until aged 69 years with pap-test every three years if the women have ever been sexually active remain in place. The National Cervical Screening Program of Australian Government believes that at age 70 women should consult with their doctor about whether they need to continue to have a regular Pap smear.
In conclusion, the present study support the screening policy to perform Pap test every 3 years until aged 69 years, independently to sexual activity because 34.64% of invasive cervical carcinoma has been diagnosed in > 65 years old women. Consequently, it is necessary to early diagnose to the decrease to mortality, morbidity and direct management costs of disease.
